Insilico Medicine and ASKA Pharmaceutical Expand AI Partnership to Tackle Chronic Gynecological Conditions Globally

Insilico Medicine and ASKA Pharmaceutical use generative AI to discover new targets for endometriosis and uterine fibroids, targeting unmet needs in gynecology.

By: AXL Media

Published: Mar 24, 2026, 12:28 PM EDT

Source: Information for this report was sourced from InSilico Medicine

Accelerating Drug Discovery for Underserved Women’s Health Needs

Insilico Medicine and ASKA Pharmaceutical have announced an expanded strategic research collaboration aimed at addressing major unmet medical needs in gynecology. Announced on March 24, 2026, the partnership focuses on identifying high potential therapeutic targets for conditions that have historically suffered from limited treatment options and diagnostic complexities. By combining ASKA’s deep clinical expertise in obstetrics and gynecology with Insilico’s generative artificial intelligence, the companies intend to streamline the path from biological hypothesis to clinical validation for conditions like endometriosis.

Utilizing Generative AI to Navigate Complex Biological Landscapes

The collaboration centers on the use of PandaOmics, Insilico’s proprietary target identification engine, to explore disease hypotheses with high translational potential. According to the announcement, the project will be spearheaded by Insilico’s Target Discovery team in Hong Kong, utilizing the recently unveiled Target Identification Pro (TargetPro) framework. This AI driven system integrates multi-modal data into disease specific models, allowing researchers to identify predictive patterns that outpace traditional models in accurately forecasting which therapeutic targets are most likely to succeed in human clinical trials.

Addressing the Global Burden of Endometriosis and Uterine Fibroids

Gynecological diseases represent a substantial global health burden, with the World Health Organization estimating that endometriosis alone affects approximately 190 million women. Uterine fibroids and adenomyosis impact an even larger demographic, often co-occurring and severely degrading reproductive health and quality of life. Dr. Frank Pun, Head of Insilico Medicine’s Hong Kong site, noted that previous preclinical validations of AI nominated targets in this field prove that technology can uncover actionable insights within the intricate biological frameworks of women’s diseases.